Drugs / Lerotinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04415853 | Jan 2021 → Aug 2026 overdue | esophageal cancer | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lerotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04415853 ↗ |